Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/11/2025 | $15.00 | Buy | B. Riley Securities |
| 7/30/2025 | $12.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 7/23/2025 | $12.00 | Buy | Craig Hallum |
| 8/5/2022 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 11/11/2021 | $33.00 → $30.00 | Overweight | Keybanc |
| 10/15/2021 | $26.00 | Outperform | Cowen |
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced the publication of a new systematic review demonstrating that the AVISE Lupus algorithm delivers markedly superior diagnostic accuracy and consistency across patient populations compared with conve
CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates. Three Months Ended March 31, 2026 2025Unaudited. In thousands, except ASP data. Revenue $17,306 $15,498 Gross margin 59.0% 58.9%Operating expenses $13,619 $12,488 Operating loss $(3,414) $(3,365)Net loss $(3,967) $(3,752)Adjusted EBITDA $(2,160) $(2,508)Trailing-twelve-month average selling price (ASP) $444 $419 Cash and cash equivalents $21,513 $11,194 First Quarter 2026 Highlights: Achieved record total revenue of $17.3 million, an increas
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) that morning to review the Company's results. Conference Call & Webcast: U.S. dial-in: 877-407-0890International dial-in: +1 201-389-0918Webcast: Available via the Exagen Investor Relations website at investors.exagen.com Replay: A telephone replay will be available until Monday, May 25, 2026
4 - EXAGEN INC. (0001274737) (Issuer)
4 - EXAGEN INC. (0001274737) (Issuer)
4 - EXAGEN INC. (0001274737) (Issuer)
B. Riley Securities initiated coverage of Exagen with a rating of Buy and set a new price target of $15.00
KeyBanc Capital Markets upgraded Exagen from Sector Weight to Overweight and set a new price target of $12.00
Craig Hallum initiated coverage of Exagen with a rating of Buy and set a new price target of $12.00
S-8 - EXAGEN INC. (0001274737) (Filer)
10-Q - EXAGEN INC. (0001274737) (Filer)
8-K - EXAGEN INC. (0001274737) (Filer)
3/A - EXAGEN INC. (0001274737) (Issuer)
3 - EXAGEN INC. (0001274737) (Issuer)
4 - EXAGEN INC. (0001274737) (Issuer)
CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune resea
CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, President and CEO of Exagen. "Kamal has been extremely supportive throughout my time with the Company, and I am very appreciative of his dedication to our customers and organization. I appreci
CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates. Three Months Ended March 31, 2026 2025Unaudited. In thousands, except ASP data. Revenue $17,306 $15,498 Gross margin 59.0% 58.9%Operating expenses $13,619 $12,488 Operating loss $(3,414) $(3,365)Net loss $(3,967) $(3,752)Adjusted EBITDA $(2,160) $(2,508)Trailing-twelve-month average selling price (ASP) $444 $419 Cash and cash equivalents $21,513 $11,194 First Quarter 2026 Highlights: Achieved record total revenue of $17.3 million, an increas
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) that morning to review the Company's results. Conference Call & Webcast: U.S. dial-in: 877-407-0890International dial-in: +1 201-389-0918Webcast: Available via the Exagen Investor Relations website at investors.exagen.com Replay: A telephone replay will be available until Monday, May 25, 2026
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 877-407-0890International dial-in: +1 201-389-0918Webcast: Available via the Exagen investor relations website at investors.exagen.com Replay: A telephone replay will be available until Tuesday, March 24, 2026: U.
SC 13G/A - EXAGEN INC. (0001274737) (Subject)
SC 13G/A - EXAGEN INC. (0001274737) (Subject)
SC 13G/A - EXAGEN INC. (0001274737) (Subject)